Cathepsins: Novel opportunities for antibody therapeutics in cancer

Archive ouverte

David, Timothée | Du Roure, Pénélope Desroys | Mallavialle, Aude | Laurent-Matha, Valérie | Roger, Pascal | Guiu, Séverine | Chardès, Thierry | Liaudet-Coopman, Emmanuelle

Edité par CCSD ; Wiley -

International audience. Cathepsins, the most abundant lysosomal proteases, have key functions in cell maintenance and homeostasis. They are overexpressed and hypersecreted in cancer and associated with poor prognosis. Secreted cathepsins display pro‐tumour activities in the tumour microenvironment and thus represent interesting molecular targets in oncology. Recently, several antibody‐based cancer therapies have targeted the pro‐tumour activity of the extracellular cathepsin pool, altering several cancer hallmarks, but not the intracellular cathepsin levels that are often crucial for cell homeostasis. In this mini‐review, we describe advances in antibodies against extracellular cathepsins in cancer, and their effect on the proteolytic cascade, matrix remodelling, proliferation, and modulation of the anti‐cancer immune response. We also discuss the add‐on value of combination strategies (anti‐cathepsin antibodies with chemotherapy and/or biologics) that make anti‐cathepsin antibodies a new opportunity for disease management.

Suggestions

Du même auteur

Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies

Archive ouverte | David, Timothée | CCSD

International audience. BackgroundTriple-negative breast cancer (TNBC) treatment is currently restricted to chemotherapy. Hence, tumor-specific molecular targets and/or alternative therapeutic strategies for TNBC ar...

Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer. Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer: Antibody-based immunomodulatory therapy of breast cancer

Archive ouverte | David, Timothée | CCSD

International audience. Background and purpose: Triple-negative breast cancer (TNBC) has poorer outcomes than other breast cancer (BC) subtypes, including HER2+ BC. Cathepsin D (CathD) is a poor prognosis marker ov...

A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer

Archive ouverte | Desroys Du Roure, Pénélope | CCSD

International audience. Introduction: Triple-negative breast cancer (TNBC) prognosis is poor. Immunotherapies to enhance the antibody-induced natural killer (NK) cell antitumor activity are emerging for TNBC that is...

Chargement des enrichissements...